Tag Archives: ex vivo lentiviral therapy

This blog was written by Deanna Petersen, Chief Business Officer of AvroBio, as part of the From The Trenches feature of LifeSciVC.   It seems so clear now: gene therapy is on a roll.  As 2017 came to a close, the

The field of gene and cell therapy has witnessed an unprecedented few months, almost unimaginable only a few years ago. It’s worth pausing to reflect on some of the recent highlights: FDA approval of two chimeric antigen receptor (CAR) T-cell